Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Amgen
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Timothy_P._Walbert
|
| gptkbp:focusesOn |
immunology
rheumatology rare diseases |
| gptkbp:formerName |
gptkb:Horizon_Pharma
|
| gptkbp:foundedIn |
2008
|
| gptkbp:founder |
gptkb:Timothy_P._Walbert
|
| gptkbp:headquartersLocation |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Horizon Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Krystexxa
gptkb:Procysbi gptkb:Ravicti gptkb:Tepezza |
| gptkbp:numberOfEmployees |
~2,000 (2022)
|
| gptkbp:stockExchange |
gptkb:Nasdaq
|
| gptkbp:tradedOn |
gptkb:Nasdaq:_HZNP
|
| gptkbp:website |
https://www.horizontherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Amgen
gptkb:PhRMA |
| gptkbp:bfsLayer |
6
|